Chinese biotech firms are pursuing global expansion, deemed 'irreversible' by insiders, despite US investment restrictions and national security measures. This expansion continues even as the US implements barriers to the American market.

China’s biotech firms are pressing ahead with global expansion, a trend industry insiders describe as “irreversible”, even as Washington rolls out investment restrictions and national security measures aimed at slowing their advance. “The US has erected numerous regulatory and non-tariff barriers for Chinese companies seeking to enter the American market,” said Zhang Jun, co-head of the global healthcare group at Chinese investment bank Citic Securities, at the Hong Kong Exchanges and Clearing’s...